newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Seeking Alpha
Legend Bio rises after early-stage data for in vivo CAR-T therapy.
Legend Biotech's LB2501 is an in vivo CAR-T therapy targeting B-cell non-Hodgkin lymphoma.
KEY POINTS
LB2501 showed initial positive results in an early-stage human clinical trial.
Legend Biotech's stock rose approximately 26% following the trial announcement.
LB2501 represents a novel approach by delivering CAR-T therapy directly in vivo.
Legend Bio rises after early-stage data for in vivo CAR-T therapy
Jun 02, 2026, 11:07 AM ETLigand Pharmaceuticals Incorporated (LGND) StockBy : Dulan Lokuwithana, SA News Editor
Comment
(1)
Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin lymphoma, the most common form of non-Hodgkin lymphoma.
Citing data
Newsletters for Every Investor
Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters